Firm has two systemic therapies and one topical treatment in Phase I.
Nabriva Therapeutics closed a E15 million (about $22.18 million) financing round to bolster its program with drug-resistant antibiotics. The company believes that this funding extends its cash reach to 2011.
Nabriva reports raising E57.4 million, or roughly $84.87 million, in total equity since its foundation in 2006. Existing investors Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures, and Novartis Venture Fund participated in the most recent round.
Nabriva focuses on developing a class of antibiotics called pleuromutilins for serious infections caused by resistant pathogens. The firm’s systemically available pleuromutilin therapies are at the Phase I stage and are expected to enter Phase II next year. Nabriva says that this latest financing round will support the generation of Phase II efficacy data in complicated skin and skin structure infections (CSSI).
Pleuromutilins interfere with bacterial protein synthesis via a specific interaction with the 23S rRNA of the 50S bacterial ribosome subunit. These compounds offer a distinct profile and show no cross-resistance with any other class of antibiotics, according to Nabriva.
Nabriva has two systemic products, BC-3205 and BC-3781, which are being developed for both oral and IV administration. They are intended for the treatment of multidrug-resistant CSSI and moderate-to-severe pneumonia. The company also has a Phase I nonsystemic pleuromutilin product candidate, BC-7013, being developed for the topical treatment of a number of bacterial-associated or -derived dermatological diseases.